Those looking for recent explosions to the upside on the OTC should take a close gander at Cure Pharmaceutical Holding Corp (OTCMKTS: CURR). The stock has been totally on fire over the past week, with shares rising as much as 200% in that time on a massive jump in volume. The float here is tiny, at under 9 million shares, which no doubt contributed to the mode of action we see on the chart.
Springing the move, the company just announced a few days ago that it has signed a term sheet with Therapix Biosciences Ltd. (Nasdaq:TRPX), a specialty, clinical-stage pharmaceutical company developing cannabinoid-based treatments, to acquire the non-pain assets of Therapix, subject to the completion of the related conditions. According to the company’s release, “these assets include several clinical drug candidates as well as two pre-clinical drug candidates.”
Cure Pharmaceutical Holding Corp (OTCMKTS: CURR) casts itself as a specialty pharmaceutical and bioscience company, develops drug formulation and delivery technologies.
The company markets CUREfilm dietary supplements, such as Melatonin-based sleep aid CUREfilm. It is also developing CUREfilm prescription and over-the-counter pharmaceutical drugs, including high dose vitamin D3, Sildenafil, PEA and dronabinol combination, Benzocaine, and Isoniazid. In addition, the company researches high dose electrolytes and various actives for veterinary applications.
CURE Pharmaceutical Holding Corp. has a development agreement with Therapix Biosciences Ltd. for formulating and developing pharmaceutical products. The company is based in Oxnard, California.
Moreover, CURE Pharmaceutical is a fully integrated and progressive drug delivery company. CURE is also a preeminent developer and manufacturer of the most advanced oral thin film (CureFilm) on the market today with an industry leading full service cGMP manufacturing facility. CURE offers the most advanced development and manufacturing of CureFilm pharmaceutical and veterinarian products in a patented and proprietary delivery system. Alongside its stand-alone CureFilm™ technology, CURE has developed an array of products in cutting-edge delivery platforms, such as sublingual and transdermal applications. The CURE Team has extensive experience formulating and manufacturing OTC products, pharmaceuticals, and veterinary medications placing quality and service as our top priorities, thus earning us the trust and respect of customers worldwide.
According to company materials, “CURE Pharmaceutical is a vertically integrated drug delivery and development company committed to improving drug efficacy, safety and the patient experience through its proprietary drug dosage forms and delivery systems. CURE has a full-service cGMP manufacturing facility and is a pioneering developer and manufacturer of a patented and proprietary delivery system (CUREfilm™), one of the most advanced oral thin film on the market today. CURE is developing an array of products in cutting-edge delivery platforms and partners with biotech and pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the U.S., Canada, Israel and Germany, among other markets. The company’s mission is to improve people’s lives by redefining how medicines are delivered and experienced.”
Find out when $CURR reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
We’ve witnessed more than 120% added to share values of the stock over the past week of action, a rally that has pushed up against longer standing distributive pressure in the stock. Furthermore, the stock has seen interest climb, with an increase in recent trading volume of just shy of 490% above the average volume levels in play in this stock over the longer term.
This should not be overlooked due to the extremely small float size in the stock (of 8.6 million shares).
“The proposed acquisition has the potential to build on our existing relationship with Therapix and create unique value by combining Therapix’ promising clinical programs with CURE’s proprietary drug delivery technology and manufacturing capabilities,” said Rob Davidson, CEO and Chairman of CURE Pharmaceutical. “Furthermore, this transaction is a further step in CURE’s efforts toward up-listing to the NASDAQ.”
At this time, carrying a capital value in the market of $53.5M, CURR has a reserve ($841K) of cash on the books, which compares with about $4M in total current liabilities. One should also note that debt has been growing over recent quarters. CURR is pulling in trailing 12-month revenues of $253K. In addition, the company is seeing major top-line growth, with y/y quarterly revenues growing at 228.7%. We will update the story again soon as developments transpire. Sign-up for continuing coverage on shares of $CURR stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $CURR, either long or short, and we have not been compensated for this article.